- Home
- DWSN vs BNR Comparison
DWSN vs BNR Comparison
Compare DWSN & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DWSN
- BNR
- Stock Information
- Founded
- DWSN 1952
- BNR 2014
- Country
- DWSN United States
- BNR China
- Employees
- DWSN N/A
- BNR N/A
- Industry
- DWSN Oil & Gas Production
- BNR Medical Specialities
- Sector
- DWSN Energy
- BNR Health Care
- Exchange
- DWSN Nasdaq
- BNR Nasdaq
- Market Cap
- DWSN N/A
- BNR 29.1M
- IPO Year
- DWSN N/A
- BNR 2020
- Fundamental
- Price
- DWSN $1.26
- BNR $2.40
- Analyst Decision
- DWSN
- BNR
- Analyst Count
- DWSN 0
- BNR 0
- Target Price
- DWSN N/A
- BNR N/A
- AVG Volume (30 Days)
- DWSN 6.9K
- BNR 50.4K
- Earning Date
- DWSN 05-16-2025
- BNR 05-28-2025
- Dividend Yield
- DWSN N/A
- BNR N/A
- EPS Growth
- DWSN N/A
- BNR N/A
- EPS
- DWSN N/A
- BNR N/A
- Revenue
- DWSN $74,154,000.00
- BNR $70,669,261.00
- Revenue This Year
- DWSN N/A
- BNR $136.32
- Revenue Next Year
- DWSN N/A
- BNR N/A
- P/E Ratio
- DWSN N/A
- BNR N/A
- Revenue Growth
- DWSN N/A
- BNR N/A
- 52 Week Low
- DWSN $1.08
- BNR $2.18
- 52 Week High
- DWSN $2.10
- BNR $8.99
- Technical
- Relative Strength Index (RSI)
- DWSN 51.02
- BNR 23.94
- Support Level
- DWSN $1.08
- BNR $2.30
- Resistance Level
- DWSN $1.39
- BNR $2.78
- Average True Range (ATR)
- DWSN 0.07
- BNR 0.32
- MACD
- DWSN 0.01
- BNR 0.04
- Stochastic Oscillator
- DWSN 58.06
- BNR 16.91
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.